Mosquitoes that landed on surfaces coated with the antimalarial compound atovaquone were completely blocked from developing Plasmodium falciparum (P. falciparum), the parasite that causes malaria, according to new research led by Harvard T.H. Chan School of Public Health.
The study showed that atovaquone—an active ingredient in medication that’s commonly used in humans to prevent and treat malaria—can be absorbed through mosquitoes’ tarsi (legs) and prevents the insects from developing and spreading the parasite. The findings indicate that treating bed nets with atovaquone or similar compounds would be an effective way to reduce the burden of malaria while significantly mitigating the growing problem of insecticide resistance.
“Mosquitoes are amazingly resilient organisms that have developed resistance against every insecticide that has been used to kill them. By eliminating malaria parasites within the mosquito rather than killing the mosquito itself, we can circumvent this resistance and effectively prevent malaria transmission,” said Flaminia Catteruccia, professor of immunology and infectious diseases. “Ultimately, the use of antimalarials on mosquito nets could help eliminate this devastating disease. It’s a simple but innovative idea that’s safe for people who use mosquito nets and friendly to the environment.”
The study was published online in Nature on February 27, 2019.
Malaria poses a risk to nearly half of the world’s population. Annually, more than 200 million people become sick with malaria and more than 400,000 people die from it. During the past 20 years, bed nets treated with long-lasting insecticides that kill mosquitoes have significantly reduced the global malaria burden. It’s estimated that such bed nets are responsible for 68% of all malaria cases averted since 2000. Recent years, however, have seen a surge in mosquitoes that are resistant to the most commonly used insecticides. In some malaria hot spots, there is near total resistance to pyrethroids, one of the key groups of insecticides currently in use. The waning effectiveness of insecticides is a public health emergency that threatens to undo decades of progress toward controlling malaria and highlights the urgent need to develop new approaches to stop the spread of the disease.
For this study, the researchers reasoned that they could introduce antimalarial compounds to Anopheles mosquitoes in a way that’s similar to a mosquito making contact with insecticides on a bed net. Rather than kill the mosquitoes, the aim was to give them a prophylactic treatment so that they could not develop and transmit the malaria-causing parasite.
To test the approach, they coated glass surfaces with atovaquone and covered them with a plastic cup. Female mosquitoes were then introduced into the cup. Prior to or immediately after the mosquitoes made contact with the atovaquone-coated glass, the researchers infected them with P. falciparum. Over the course of the study, mosquitoes were exposed to different concentrations of atovaquone and were kept in the cups for different amount of times.
The study found that P. falciparum development was completely blocked at relatively low concentrations of atovaquone (100 ?mol per m2) and when mosquitoes were exposed for just 6 minutes, which is comparable to the time wild mosquitoes spend on insecticide-treated bed nets. The researchers had similar success when using other compounds similar to atovaquone. While atovaquone effectively killed parasites, it had no effects on mosquito lifespan or reproduction.
“When we put these data into a mathematical model using real-world data on insecticide resistance, bed net coverage and malaria prevalence, it showed that supplementing conventional bed nets with a compound like atovaquone could appreciably reduce malaria transmission under almost any conditions we had data for in Africa,” said Douglas Paton, research fellow and lead author of the paper. “What got us really excited is that it also showed that this new intervention would have the greatest impact in areas with the highest levels of mosquito insecticide resistance.”
The Latest on: Atovaquone
via Google News
The Latest on: Atovaquone
- Standby Emergency Treatment of Malaria in Travelerson October 4, 2020 at 5:00 pm
New developments such as improved rapid malaria tests and their wider distribution together with the availability of effective, well-tolerated malaria treatments, such as atovaquone/proguanil ...
- Long-Term Malaria Prophylaxis for Travelerson October 1, 2020 at 5:00 pm
Priority should be given to drugs that may be used for both chemoprophylaxis and standby, such as mefloquine and atovaquone-proguanil. Expatriates who live where malaria is hyper- or holoendemic ...
- Misdiagnosis related to premature diagnostic closure during the COVID-19 pandemicon September 27, 2020 at 5:00 pm
Given the patient’s hypersensitivity reactions to sulfonamides and clindamycin, she was discharged with atovaquone for P. jirovecii pneumonia. Two weeks later, the patient presented to her scheduled ...
- FDA ticks off list of grievances over California drug repackager's quality issues in warning letteron September 11, 2020 at 7:27 am
In December, the FDA blasted Massachusetts-based Lohxa in a warning letter for giving lots of repackaged unit dose drugs, including pneumonia treatment atovaquone oral suspension, expiration ...
- Anti-Malarial Drugs Market 2018 New Innovations Trends, Research, Global Share and Growth Factor till 2027on September 7, 2020 at 11:29 am
The MarketWatch News Department was not involved in the creation of this content. Sep 07, 2020 (AmericaNewsHour) -- The report titled "Anti-Malarial Drugs Market: Global Demand Analysis ...
- Plasmodium spp. Agent Information Sheeton August 19, 2020 at 5:00 pm
Presumptive first line treatments for Plasmodium falciparum or plasmodium vivax include atovaquone-proguanil, artemether lumefantrine, quinine, chloroquine (if chloroquine sensitve), doxycycline, ...
- Health Informationon August 18, 2020 at 10:40 pm
Medicines that protect against malaria in this area include mefloquine (Lariam), doxycycline , or atovaquone/proguanil (Malarone). The best drug for you depends on your itinerary and on a number ...
- Home – Articles, Analysis, Commenton May 28, 2020 at 3:10 am
Resistance to a commonly used antimalarial medication, Atovaquone, can’t spread to the general human population, a new research found. Malcolm Turnbull says bluntly that he expects the coming ...
- Valley doctors testing medication combination in COVID-19 treatment clinical trialon May 5, 2020 at 5:36 pm
The medications being tested are atovaquone, which is used to prevent malaria, and azithromycin, a common antibiotic. 25 COVID-19 patients in the valley will be part of the first trial in Arizona.
- Does Atovaquone Interact with other Medications?on May 25, 2017 at 10:05 am
These medications are not usually taken together. Consult your healthcare professional (e.g., doctor or pharmacist) for more in formation. Selected from data included with permission and ...
via Bing News